# UK Personalized Medicine Market > UK Personalized Medicine Market Research Report By Product Outlook (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness), By Application Outlook (Oncology, CNS, Immunology, Respiratory, Others) and By End-User Outlook (Hospitals, Diagnostic Centers, Research Academic Institutes, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.42% - **2024:** $ 37.29 Billion - **2025:** $ 39.69 Billion - **2035:** $ 73.97 Billion - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) **Report ID:** MRFR/HC/43628-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-personalized-medicine-market-45308 --- ## Market Summary ## **UK Personalized Medicine Market Overview** As per MRFR analysis, the UK Personalized Medicine Market Size was estimated at 25.05 (USD Billion) in 2023.The UK Personalized Medicine Market is expected to grow from 26.85 (USD Billion) in 2024 to 59.3 (USD Billion) by 2035. The UK Personalized Medicine Market CAGR (growth rate) is expected to be around 7.468% during the forecast period (2025-2035). **Key UK Personalized Medicine Market Trends Highlighted** Current developments in genetics and biotechnology are driving notable changes in the UK personalized medicine market. Genetic testing's incorporation into routine medical procedures is essential for customizing care to meet the needs of each patient and enhancing results in a number of areas, such as chronic illnesses and oncology. Moreover, a strong basis for customized treatment is being established by the government's dedication to boosting funding for genomic research, which is demonstrated by programs like the 100,000 Genomes Project. The development of tailored therapeutics is ultimately supported by the tight collaboration between pharmaceutical corporations and healthcare professionals, which is encouraged by the increasing understanding of the significance of patient-centric treatments. As more healthcare professionals embrace cutting-edge technologies that enable individualized treatment options, opportunities in the UK market are expanding. More effective patient monitoring and interaction are made possible by the growth of digital health solutions including telemedicine, mobile health apps, and digital therapies. Furthermore, collaborations between academic institutions and business leaders foster an atmosphere that is conducive to innovation, especially in fields like the development of novel drugs and biomarkers. Big data analytics and artificial intelligence (AI) have been increasingly popular in the healthcare industry in recent years, aiding in the optimization of treatment regimens based on extensive datasets. In order to implement interventions that are more accurate and successful, the NHS in the UK is investigating ways to use these technologies. The landscape is also being shaped by the focus on empirical data and patient-reported results, which enables continuous improvement of individualized treatment plans. All things considered, these patterns point to a bright future for the UK personalized medicine market, with ongoing developments certain to greatly improve patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Personalized Medicine Market Drivers** **Increasing Prevalence of Chronic Diseases** The UK is experiencing a significant rise in chronic diseases, particularly cancer, diabetes, and cardiovascular diseases, which are crucial drivers of the UK Personalized Medicine Market. Reports suggest that approximately 38% of the population in the UK will be diagnosed with some form of cancer in their lifetime, with the National Health Service (NHS) noting that there were over 367,000 new cancer cases in 2019 alone. The increase in demand for personalized medicine is directly linked to the need for targeted therapies that improve treatment outcomes while reducing side effects. Organizations like Cancer Research UK and the NHS are at the forefront, pushing initiatives to incorporate personalized medicine approaches into their treatment protocols, reflecting a growing commitment to tailored healthcare solutions. **Advancements in Genomic Technologies** The rapid advancements in genomic technologies are significantly propelling the UK Personalized Medicine Market forward. The UK Government has invested heavily in genomic research, including the 100,000 Genomes Project, which has sequenced the genomes of approximately 100,000 individuals to better understand genetic contributions to disease. Innovations such as next-generation sequencing (NGS) have become more cost-effective and accessible, allowing healthcare professionals to offer personalized treatments based on a patient's genetic makeup. This shift is expected to drastically increase the precision of cancer treatment, monitoring, and prevention. The involvement of organizations such as the Wellcome Trust and UK Biobank brings additional resources and scientific expertise, further enhancing the market's growth potential. **Supportive Government Policies and Funding** The UK government has established various supportive policies and funding mechanisms that actively encourage the growth of the UK Personalized Medicine Market. Initiatives such as the UK Life Sciences Strategy promote investment and innovation in personalized medicine. According to the Department of Health and Social Care, public funding for life sciences, including personalized medicine, was set to increase to over 1 billion annually by 2025. Such governmental efforts not only foster research and development but also help in building partnerships between academic institutions, private industry, and healthcare providers. Organizations like Innovate UK are instrumental in driving collaborations and facilitating projects aimed at integrating personalized medicine into mainstream healthcare. **UK Personalized Medicine Market Segment Insights** **Personalized Medicine Market Product Outlook Insights** The UK Personalized Medicine Market, particularly under the Product Outlook segment, has seen considerable advancements and holds significant potential for future development. It has shown a robust growth trajectory, reflecting a deeper integration of individualized treatments into mainstream healthcare. Personalized Medicine Diagnostics stands out for its critical role in identifying specific patient needs through advanced diagnostic tools, enabling tailored therapies that enhance treatment efficacy and minimize side effects. This strategic approach is vital in the UK, where healthcare systems are increasingly emphasizing evidence-based practices and outcomes. In parallel, Personalized Medicine Therapeutics has gained importance as it focuses on the development of customized therapies based on genetic, environmental, and lifestyle factors. This has led to more successful interventions in treating complex diseases such as cancer, diabetes, and rare genetic disorders, thus reshaping patient experiences and clinical outcomes. Additionally, Personalized Medical Care has emerged as a cornerstone in the healthcare landscape, promoting patient-centered approaches that align with the growing demand for tailored healthcare experiences among UK citizens. As a result, healthcare professionals are better equipped to administer precise healthcare strategies that directly cater to individual needs and preferences, enhancing adherence to treatment plans and overall satisfaction. Furthermore, the trend towards Personalized Nutrition and Wellness is becoming increasingly significant, as it offers customized dietary recommendations based on an individual's genetic makeup, lifestyle, and health status. This aligns with the UK public's heightened awareness of health maintenance and prevention, as well as the government's focus on addressing chronic diseases through preventative measures. Collectively, these segments within the Product Outlook of the UK Personalized Medicine Market are reinforcing the shift towards a more customized, effective, and preventative healthcare model, thereby addressing both existing health challenges and emerging market needs. The continuous evolution of these categories is not only reshaping the industry's landscape but also indicating numerous opportunities for market players to innovate and foster growth in the sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Personalized Medicine Market Application Outlook Insights** The UK Personalized Medicine Market, particularly in the Application Outlook segment, showcases a diverse range of areas such as Oncology, CNS, Immunology, Respiratory, and others, reflecting the intricate landscape of healthcare innovation. Oncology remains a prominent area, driven by the increasing prevalence of cancer and a growing demand for tailored therapies that enhance treatment efficacy and minimize side effects. Central Nervous System (CNS) disorders, including conditions like Alzheimer's and multiple sclerosis, draw attention due to the complex biology involved and the need for personalized approaches to break through the limitations of traditional therapies. In the sphere of Immunology, the rise of immunotherapies marks a significant shift, empowering the immune system to combat diseases more effectively, while the Respiratory segment focuses on personalized treatments that address specific patient profiles, especially amid rising respiratory conditions. The robust growth framework of this market segment is further supported by advancements in genomic technologies and big data analytics that enable precise patient stratification, which in turn drives the UK Personalized Medicine Market revenue and fosters a more effective healthcare ecosystem. These trends collectively highlight the increasing importance of tailored medicine in addressing unique patient needs within the UK healthcare system, presenting both challenges and vast opportunities for growth. **Personalized Medicine Market End-User Outlook Insights** The UK Personalized Medicine Market demonstrates a robust End-User Outlook, which is essential in determining how tailored healthcare solutions are adopted and utilized. Among various users, hospitals play a pivotal role in providing cutting-edge treatments that enhance patient outcomes through personalized approaches, which directly influence patient care and experience. Diagnostic centers contribute significantly by advancing precision diagnostics, with technologies enabling early disease detection and effective monitoring, thereby ensuring the right treatment is administered to the right patient at the right time. Research and academic institutes are vital as they drive innovation through the exploration and validation of new therapies, fostering collaboration between scientific research and practical applications in healthcare. Additionally, other users encompass various entities, including pharmaceutical companies and regulatory bodies, which support the deployment and regulation of personalized medicine. With a collective effort from these segments, the UK Personalized Medicine Market is positioned for sustained growth, delivering targeted therapies that enhance treatment efficacy and improve healthcare delivery, aligning closely with national health priorities. Notably, the integration of these segments fuels advancements in medical research while responding to the increasing demand for customized healthcare solutions across the UK. **UK Personalized Medicine Market Key Players and Competitive Insights** The UK Personalized Medicine Market is rapidly evolving, characterized by significant advancements in biotechnology, genetic research, and diagnostic technologies. With a growing emphasis on tailoring medical treatments to individual patient profiles, the competitive landscape is marked by innovative firms that are leveraging cutting-edge research to develop targeted therapies and precision medicines. The market is driven by factors such as increasing awareness of personalized healthcare, expanding genomic research initiatives, and the rising prevalence of chronic diseases, which necessitate customized treatment approaches. As stakeholders such as biopharmaceutical companies, research institutions, and health service providers collaborate to enhance patient outcomes, the competition in this sector continues to intensify, presenting both opportunities and challenges for established and emerging players alike. Roche has established a strong foothold in the UK Personalized Medicine Market, renowned for its commitment to research and development in tailored healthcare solutions. The company's strengths lie in its robust portfolio of innovative diagnostic tools and therapies that align well with the trends in personalized medicine. With a rich history of investment in genetic profiling and biomarker discovery, Roche is well-positioned to deliver targeted treatments that optimize patient care. Furthermore, the company's strong relationships with healthcare professionals and institutions across the UK enable it to effectively implement its personalized medicine strategies, ensuring that its products meet the evolving needs of both patients and healthcare providers. This strategic engagement is crucial in enhancing Roche’s presence and competitive edge in the market. AstraZeneca plays a pivotal role in the UK Personalized Medicine Market, focusing on innovative therapies that cater to specific patient populations. The company's key products and services include advanced biologics and targeted therapies designed for oncology and other therapeutic areas, reflecting its commitment to precision medicine. AstraZeneca's strengths lie in its extensive research capabilities and collaboration with leading academic institutions and biotechnology firms, amplifying its capacity for pioneering advancements in personalized healthcare. The company has also made strategic mergers and acquisitions to bolster its portfolio, thus enhancing its market presence in the UK. By investing in biomarker research and developing partnerships within the healthcare ecosystem, AstraZeneca continues to reinforce its position as a leader in the personalized medicine arena, addressing diverse patient needs while pushing the boundaries of current therapeutic options. **Key Companies in the UK Personalized Medicine Market Include** - Roche - AstraZeneca - Amgen - Merck - Novartis - Qiagen - Pfizer - Foundation Medicine - Siemens Healthineers - GSK - Thermo Fisher Scientific - Bristol-Myers Squibb - Illumina - BioRad Laboratories - AbbVie **UK Personalized Medicine****Market****Developments** The UK Personalized Medicine Market is experiencing significant developments, particularly with partnerships and innovations surrounding leading pharmaceutical companies. Roche has launched new initiatives aimed at advancing precision medicine, while AstraZeneca is enhancing its portfolio by focusing on genomic medicine. Merck announced a collaboration with Foundation Medicine in September 2023 to expand its precision oncology approaches, indicating a strong market interest in tailored therapies. Novartis continues to build its position through strategic research partnerships that emphasize personalized patient care. Growth in market valuation is notable, as GSK and Pfizer are investing heavily in genomics and data analytics to enhance patient treatment outcomes. Additionally, key mergers such as Illumina’s acquisition of Grail, finalized in early 2022, have significantly influenced market dynamics. Recent data from the UK government suggests that personalized medicine is anticipated to drive healthcare efficiency and improve patient outcomes, contributing to a projected increase in market size and economic impact in the coming years. As of October 2023, Thermo Fisher Scientific's advancements in laboratory technologies are expected to further strengthen the capabilities of personalized medicine initiatives across the UK healthcare landscape. **UK Personalized Medicine Market Segmentation Insights** **Personalized Medicine Market****Product****Outlook** - Personalized Medicine Diagnostics - Personalized Medicine Therapeutics - Personalized Medical Care - Personalized Nutrition and Wellness **Personalized Medicine Market****Application****Outlook** - Oncology - CNS - Immunology - Respiratory - Others **Personalized Medicine Market****End-User****Outlook** - Hospitals - Diagnostic Centers - Research Academic Institutes - Others -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Advancements in Genomic Research Recent advancements in genomic research are significantly influencing the personalized medicine market. The UK has seen substantial investment in genomic studies, which have led to breakthroughs in understanding genetic disorders and their treatment. The 100,000 Genomes Project, for instance, has provided invaluable data that is being utilized to develop personalized therapies. This initiative has not only enhanced the understanding of rare diseases but also paved the way for more effective treatments in oncology and other fields. As genomic research continues to evolve, it is expected that the personalized medicine market will experience accelerated growth, with an increasing number of therapies being developed based on genetic insights. ### Regulatory Framework Enhancements The regulatory landscape in the UK is evolving to better accommodate the needs of the personalized medicine market. Recent updates to regulations are designed to streamline the approval process for innovative therapies, making it easier for companies to bring new treatments to market. The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced guidelines that promote the development of personalized medicines while ensuring patient safety. This supportive regulatory environment is likely to encourage investment in research and development, as companies feel more confident in navigating the approval process. As a result, the personalized medicine market is expected to see an influx of new therapies, further enhancing treatment options for patients. ### Rising Demand for Targeted Therapies The increasing prevalence of chronic diseases in the UK is driving the demand for targeted therapies within the personalized medicine market. As healthcare providers seek more effective treatment options, the focus on therapies tailored to individual genetic profiles becomes paramount. Reports indicate that the market for targeted therapies is expected to grow at a CAGR of approximately 10% over the next five years. This growth is largely attributed to advancements in genomics and biotechnology, which enable the development of treatments that are more effective and have fewer side effects. Consequently, the personalized medicine market is likely to expand as both patients and healthcare professionals recognize the benefits of these tailored approaches. ### Growing Public Awareness and Acceptance Public awareness regarding the benefits of personalized medicine is on the rise in the UK, contributing to the market's growth. Educational campaigns and media coverage have played a crucial role in informing patients about the advantages of personalized treatments. As individuals become more knowledgeable about their health options, they are more likely to seek out personalized therapies. This shift in patient attitudes is reflected in surveys indicating that over 70% of patients are willing to undergo genetic testing if it leads to more effective treatment options. Consequently, the personalized medicine market is poised to benefit from this growing acceptance, as healthcare providers adapt to meet the evolving demands of informed patients. ### Investment in Healthcare Infrastructure The UK government is actively investing in healthcare infrastructure, which is likely to bolster the personalized medicine market. Initiatives aimed at enhancing healthcare facilities and integrating advanced technologies are paving the way for more efficient delivery of personalized therapies. The National Health Service (NHS) has allocated substantial funding to support the implementation of precision medicine initiatives, which are expected to improve patient outcomes. This investment is crucial, as it not only facilitates access to cutting-edge treatments but also encourages collaboration between research institutions and healthcare providers. As a result, the personalized medicine market is anticipated to thrive in an environment that supports innovation and accessibility. ## Future Outlook The [Personalized Medicine Market](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) is projected to grow at a 6.42% CAGR from 2025 to 2035, driven by advancements in genomics, technology integration, and increasing demand for tailored therapies. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in biobanking for personalized drug development and research. By 2035, the personalized medicine market is expected to see substantial growth and innovation. ## Segment Insights ### By Product: Personalized Medicine Diagnostics (Largest) vs. Personalized Medicine Therapeutics (Fastest-Growing) The UK personalized medicine market exhibits a diverse array of segment values, with Personalized Medicine Diagnostics leading in market share due to its essential role in tailored healthcare solutions. Personalized Medicine Therapeutics follows, marking significant growth driven by advances in drug development and a shift towards individualized treatment methodologies, attracting substantial investment and interest from stakeholders. Growth trends indicate a robust trajectory for both Personalized Medicine Diagnostics and Personalized Medicine Therapeutics, with innovations continuously shaping the landscape. Factors such as increasing prevalence of chronic diseases, rising demand for customized treatment plans, and heightened awareness of personalized healthcare options contribute to the accelerating growth rates, particularly in therapeutics as technology evolves and more patient-specific options become available. Personalized Medicine Diagnostics (Dominant) vs. Personalized Medicine Therapeutics (Emerging) Personalized Medicine Diagnostics is recognized as the dominant segment in the market, characterized by its foundational role in identifying individual patient needs and guiding treatment decisions. With advanced technologies such as genomics and molecular diagnostics, this sector ensures precise disease detection and monitoring. In contrast, Personalized Medicine Therapeutics is emerging rapidly, focusing on developing medications tailored to genetic or phenotypic profiles. This segment benefits from innovative research and collaborations, aiming to provide targeted therapies that promise enhanced efficacy and reduced side effects, positioning it as a vital area for growth and investment in the future. ### By Application: Oncology (Largest) vs. CNS (Fastest-Growing) In the UK personalized medicine market, Oncology is the largest segment, commanding a substantial share as advanced therapies and targeted treatments become prevalent. The focus on precision medicine has driven this sector, making it a cornerstone of market development. Other segments, such as CNS and Immunology, also hold notable shares but do not surpass Oncology's dominance, while Respiratory and Others contribute to the market dynamics. Oncology (Dominant) vs. CNS (Emerging) Oncology represents the dominant force in the personalized medicine landscape, fueled by significant investments in research and the increasing rate of cancer diagnoses. The availability of tailored therapies enhances patient outcomes and drives demand within this segment. In contrast, CNS, although smaller, is an emerging area characterized by growing innovation in treatment approaches such as gene therapy and biomarker identification. This segment is gaining traction as healthcare providers seek more effective strategies to address complex neurological disorders, indicating a promising trajectory for its future growth. ### By End-User: Hospitals (Largest) vs. Research & Academic Institutes (Fastest-Growing) In the UK personalized medicine market, hospitals dominate the end-user segment, capturing a significant share. These facilities are pivotal in implementing personalized therapies, leveraging advanced diagnostics and treatment options tailored to individual patient profiles. Meanwhile, diagnostic centers and other entities like research institutes exhibit notable activity, but their market shares are comparatively smaller than that of hospitals. Growth within the end-user segment is propelled by an increasing focus on precision medicine. Research and academic institutes are emerging as substantial players, driven by their role in innovative studies and development of personalized therapies. The collaboration between healthcare providers and these institutes further accelerates growth, ensuring that advancements in technology and methodology are swiftly integrated into practice. Hospitals (Dominant) vs. Diagnostic Centers (Emerging) Hospitals represent the dominant force in the UK personalized medicine market, primarily due to their extensive resources and capacity to offer comprehensive patient care. They have established rigorous infrastructures to support personalized treatments, contributing to improved patient outcomes. On the other hand, diagnostic centers are emerging as important contributors to this landscape. They specialize in advanced testing and real-time data analysis, which are crucial for the timely personalization of treatment plans. This emergence is driven by the rising demand for precise diagnostics, positioning them as essential collaborators in the overall personalized care continuum. ## Competitive Benchmarking The personalized medicine market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in genomics, biotechnology, and data analytics. Key players such as Roche (CH), Thermo Fisher Scientific (US), and GSK (GB) are strategically positioned to leverage these advancements. Roche (CH) focuses on innovation through its robust pipeline of targeted therapies, while Thermo Fisher Scientific (US) emphasizes partnerships to enhance its diagnostic capabilities. GSK (GB) is actively pursuing digital transformation initiatives to streamline its operations and improve patient outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of offerings, yet the collective strength of major companies shapes the overall market dynamics, fostering an environment ripe for collaboration and innovation. In October Roche (CH) announced a strategic partnership with a leading AI firm to develop predictive analytics tools aimed at personalizing treatment plans for oncology patients. This move is significant as it underscores Roche's commitment to integrating advanced technologies into its therapeutic approaches, potentially enhancing patient outcomes and positioning the company as a leader in precision medicine. In September GSK (GB) launched a new initiative focused on the development of personalized vaccines, targeting specific genetic markers associated with various cancers. This initiative not only reflects GSK's innovative approach but also highlights the growing trend towards personalized immunotherapy, which could redefine treatment paradigms in oncology. In August Thermo Fisher Scientific (US) expanded its genomic sequencing capabilities by acquiring a smaller biotech firm specializing in CRISPR technology. This acquisition is likely to enhance Thermo Fisher's product offerings and strengthen its position in the personalized medicine market, as CRISPR technology is pivotal for developing targeted therapies and diagnostics. As of November current trends in the personalized medicine market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may redefine how companies engage with healthcare providers and patients, emphasizing the importance of tailored solutions in a rapidly changing market. ## Recent News & Developments The UK Personalized Medicine Market is experiencing significant developments, particularly with partnerships and innovations surrounding leading pharmaceutical companies. Roche has launched new initiatives aimed at advancing precision medicine, while AstraZeneca is enhancing its portfolio by focusing on genomic medicine. Merck announced a collaboration with Foundation Medicine in September 2023 to expand its precision oncology approaches, indicating a strong market interest in tailored therapies. Novartis continues to build its position through strategic research partnerships that emphasize personalized patient care. Growth in market valuation is notable, as GSK and Pfizer are investing heavily in genomics and data analytics to enhance patient treatment outcomes. Additionally, key mergers such as Illumina’s acquisition of Grail, finalized in early 2022, have significantly influenced market dynamics. Recent data from the UK government suggests that personalized medicine is anticipated to drive healthcare efficiency and improve patient outcomes, contributing to a projected increase in market size and economic impact in the coming years. As of October 2023, Thermo Fisher Scientific's advancements in laboratory technologies are expected to further strengthen the capabilities of personalized medicine initiatives across the UK healthcare landscape. ## Report Scope | MARKET SIZE 2024 | 37.29(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 39.69(USD Billion) | | MARKET SIZE 2035 | 73.97(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) | | Segments Covered | Product, Application, End-User | | Key Market Opportunities | Advancements in genomics and biotechnology drive growth in the personalized medicine market. | | Key Market Dynamics | Growing emphasis on genetic testing drives innovation and competition in the personalized medicine market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of personalized medicine in the UK in 2024?** A: The market valuation of personalized medicine in the UK was $37.29 Billion in 2024. **Q: What is the projected market valuation for personalized medicine in the UK by 2035?** A: The projected market valuation for personalized medicine in the UK is $73.97 Billion by 2035. **Q: What is the expected CAGR for the UK personalized medicine market during the forecast period 2025 - 2035?** A: The expected CAGR for the UK personalized medicine market during the forecast period 2025 - 2035 is 6.42%. **Q: Which companies are considered key players in the UK personalized medicine market?** A: Key players in the UK personalized medicine market include Roche, Thermo Fisher Scientific, Illumina, Novartis, GSK, Bristol-Myers Squibb, Pfizer, Merck KGaA, and Amgen. **Q: What are the main segments of the UK personalized medicine market?** A: The main segments of the UK personalized medicine market include Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition and Wellness. **Q: What was the valuation of Personalized Medicine Diagnostics in 2024?** A: The valuation of Personalized Medicine Diagnostics was $7.43 Billion in 2024. **Q: How much is the Personalized Medicine Therapeutics segment expected to grow by 2035?** A: The Personalized Medicine Therapeutics segment is expected to grow from $15.0 Billion in 2024 to $30.0 Billion by 2035. **Q: What is the projected valuation for the Oncology application segment by 2035?** A: The projected valuation for the Oncology application segment is $24.0 Billion by 2035. **Q: What was the market size for hospitals as end-users in 2024?** A: The market size for hospitals as end-users was $15.0 Billion in 2024. **Q: What is the expected growth for the Personalized Nutrition and Wellness segment by 2035?** A: The Personalized Nutrition and Wellness segment is expected to grow from $6.86 Billion in 2024 to $13.41 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-personalized-medicine-market-45308*